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Abstract
Rapid documentation of respiratory specimens can have an
impact on the management of patients and their relatives in
terms of preventive and curative measures. We compared the
results of the Xpert Flu assay (Cepheid) with three real-time
RT-PCR assays using 127 nasopharyngeal samples, of which 75
were positive for influenza A (with 52 identified as A/H1N1-
2009) and 52 were positive for influenza B. The Xpert Flu assay
presented a quasi-absence of non-interpretable tests, and showed
sensitivity and specificity of 100% and 100% for Flu A, 98.4% and
100% for A/H1N1-2009, and 80.7% and 100% for Flu B.
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Rapid documentation of respiratory specimens for influenza
virus can have an impact on the management of patients and
their relatives in terms of preventive and curative measures.
Rapid antigen tests are of limited utility because negative
results need to be verified by a confirmatory technique
(usually real-time RT-PCR) due to their low sensitivity of
10–70% [1–4]. Therefore only positive results can be vali-
dated for transmission to the clinical ward. For years, real-
time RT-PCR assays were not amenable to point-of-care lab-
oratories. Very recently fully automated easy-to-use molecu-
lar systems, usable with limited technical expertise, have
been introduced: GeneXpert (Cepheid, Sunnyvale, CA,
USA), Jaguar (HandyLab, Ann Arbor, MI, USA) and FilmArray
(Idaho Technology, Salt Lake City, UT, USA). It is now time
to evaluate these new technologies within the microbiology
laboratory arsenal. The GeneXpert System is designed to
purify, concentrate, detect and identify targeted nucleic acid
sequences using a closed, self-contained, fully-integrated and
automated platform that combines on-board sample prepara-
tion with real-time PCR amplification. The Cepheid Xpert
Flu assay allows determination of Flu A and Flu B infection
and identification of 2009 H1N1 in <75 min. It is well
adapted to point-of-care (POC) laboratories because of inte-
gration (extraction, amplification and detection within a sin-
gle-use disposable cartridge) and ease of use, and has
theoretically performances that should render confirmatory
tests unnecessary.
We compared the results of the Xpert Flu assay with
three real-time RT-PCR assays routinely used in our labora-
tory. For this, a panel of 127 nasopharyngeal samples, col-
lected between 2008 and 2011, that contained influenza A
or B virus RNA was included in the study. They consisted
of 75 influenza A-positive samples (of which 52 had been
typed as A/H1N1-2009), and 52 influenza B specimens. All
samples had been submitted to nucleic acid extraction using
the EZ1 Virus Mini kit v2.0 and the EZ1 Advanced XL Bio-
robot (Qiagen, Courtaboeuf, France). The routine real-time
RT-PCR tests used for routine detection of influenza A and
B [5] and A/H1N1-2009 [6] have been previously described.
Remaining material corresponding to the specimens selected
in the panel had been stored at )70C. This material was
thawed and a total of 150 lL was mixed with 150 lL of
the lysis buffer provided by Cepheid: the resulting 300 lL
were loaded on to the cartridge and processed according
to the manufacturer’s recommendation on a 16-module
GeneXpert System.
For the six age categories – (<1 year, 1–4 years, 5–
14 years, 15–24 years, 25–49 years and >50 years) the num-
ber of patients (and sex ratio) was, respectively, 23 (0.6), 41
(1.0), 32 (1.0), 12 (1.0), 12 (0.5) and 7 (0.75).
None of these 127 samples were ‘indeterminate’ with the
Xpert Flu assay. The results are detailed in Table 1. The
Xpert Flu assay exhibited respective sensitivity (Se) and
specificity (Sp) at 100% and 100% for the detection of Flu A,
98.4% and 100% for H1N1-2009, and 80.7% and 100% for
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the detection of Flu B. From these results, it appears that
sensitivity for the detection of Flu B is lower than claimed by
the Cepheid company (1.3–77.1 TCID50/mL [CI 95%] for
FluA, 1.5–50.6 TCID50/mL [CI 95%] for FluB (http://www.
newmicro.it/doc/workshop/Workshop%20Cepheid_GeneXpert.
pdf). A detailed analysis of Flu B results indicated that the
mean Ct (SD) was 28.31 (± 4.83) in the 42 Flu B RT-PCR-
positive samples that were found positive using the Xpert
FluB test, and 33.5 (± 3.21) in the 10 Flu B RT-PCR-positive
samples that were negative using the Xpert Flu B test. The
difference was statistically significant (p < 0.05). Thus the
samples in which the amount of viral RNA was lower were
more likely to provide a false-negative result with the Flu B
Xpert test. The relatively low sensitivity for detection of
Flu B has been previously reported with observed rates of
95% and 94.6% [7,8], although other studies have reported
optimal values (100%) [9,10]. In our case, this negative point
needs to be tempered by two facts. First, the protocol that
was used in our study differs from the Cepheid-recom-
mended protocol, resulting in a dilution of the clinical sample
that is 1.25 times more important. Second, our study was
conducted with frozen samples, which may have impacted
the results by decreasing the actual viral load. However, all
specimens that appeared discrepant (RT-PCR positive/
Xpert negative for influenza b virus) were retested with
the routine RT-PCR test on thawed material: in all cases, the
second RT-PCR test confirmed the first RT-PCR result. In
contrast, the relatively low sensitivity on H1N1-2009 previ-
ously reported [7] was not confirmed in our study. How-
ever, both studies demonstrate that the sensitivity of the
Xpert Flu test on A/H1N1-2009 is equivalent or better
than that of the Xpert Flu A, which was awarded emer-
gency use authorization shortly after the beginning of the
2009 pandemic [11]. These discrepant findings require to be
confirmed by additional studies realized in realistic conditions
taking into account the innate nature of this POC test.
Indeed, European laboratories of clinical microbiology are
now following the trend towards centralization of analyses
for cost-effectiveness [12]. The new logistics frequently
increased distances between the patient and the laboratory,
thus increasing the time for transportation and delayed
results [13]. As a consequence, microbiology laboratories
are unable to contribute to timely decision-making for spe-
cific infectious diseases [12,13], including influenza during the
epidemic season, resulting in unnecessary empirical use of
antibiotics and hospitalization [14]. As clinical microbiolo-
gists, we must take into consideration the pragmatic view of
the majority of clinicians who place considerable importance
on obtaining a result within a few hours so that clinical man-
agement plans can be helped with timely laboratory docu-
mentation. As a countermeasure to this time lag between
test results and patient care, there is a growing range of
rapid diagnostic tests amenable to POC laboratories in the
vicinity of hospitalization units [15,16]. The few recent stud-
ies evaluating the Xpert Flu assay indicate that (i) the per-
formances are compatible with utilization in POC
laboratories, (ii) this assay provides results very rapidly, and
does not require confirmatory testing for Flu A, and (iii)
there is a quasi-absence of non-interpretable tests.
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